A Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
The objective of this clinical study is to evaluate the effectiveness and safety of selegiline plus docetaxel therapy compared to the standard of care - docetaxel therapy - among patients diagnosed with metastatic, castrate-resistant prostate adenocarcinoma.
Epistemonikos ID: 9d6b8f6abfc85c673692969ebd0b61fdda676fd2
First added on: May 07, 2024